Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Bl... (onoclonal antibodies for achieving a tum...)

HOME >> MEDICINE >> TECHNOLOGY

Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab

Date:8/14/2008

onoclonal antibodies for achieving a tumor regression in this disease. This may relate to the high anti-tumor activity of cytotoxic T cells recruited by blinatumomab," commented Micromet Senior Vice President and Chief Scientific Officer Patrick Baeuerle.

"This first observation of durable objective responses in relapsed, incurable patients indicates the potential blinatumomab and BiTE antibodies in general may have in fighting cancer," added Micromet Senior Vice President and Chief Medical Officer Carsten Reinhardt, M.D.

Typically antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. Previous attempts have shown the potential of T cells to treat cancer, but the therapeutic approaches tested to date have been hampered by cancer cells' ability to escape recognition by T cells. The use of antibodies that are specifically designed to engage T cells for attacking cancer cells may provide a more effective anti-tumor approach than conventional monoclonal antibodies, which require much higher doses and are typically combined with chemotherapies.

Micromet has additional clinical trials with BiTE antibodies underway, including a phase 2 clinical trial to evaluate blinatumomab for the treatment of patients with acute lymphoblastic leukemia (ALL), and a phase 1 trial investigating MT110, a BiTE antibody targeting EpCAM, in patients with lung or gastrointestinal cancers.

Micromet will host a webcast and a conference call on Monday, August 18 at 10:00 a.m. Eastern Time, (4:00 p.m. Central European Time), to discuss these results. The webcast can be accessed at: http://www.micromet-inc.com/sciencepub. To participate in the conference call, dial 866-202-4367 (U.S.) or 617-213-8845 (international), passcode: 31176615.

(1) Bargou R et al. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Scie
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Clinical Trials Bootcamp Announces Inaugural Meeting
2. Aon eSolutions Launches Clinical Trials Module
3. Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders
4. NewCardio Announces Positive Results From Third Clinical Validation Study
5. Isis Initiates Clinical Trial of CRP Drug
6. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
7. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
8. Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent
9. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
10. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
11. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain

Post Your Comments:

Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Bl...(onoclonal antibodies for achieving a tum...),Health